P2Y12 Inhibitors Outperform Aspirin in Preventing Heart Attacks and Strokes Without Raising Bleeding Risk

A meta-analysis of five trials in more than 16,000 patients showed a 23% drop in major cardiovascular events over four years with P2Y12 monotherapy replacing aspirin